%0 Journal Article
%A Pérez-Martínez, Laura
%A Romero, Lourdes
%A Muñoz-Galván, Sandra
%A Verdugo-Sivianes, Eva M
%A Rubio-Mediavilla, Susana
%A Oteo, José A
%A Carnero, Amancio
%A Blanco, José-Ramón
%T Implications of maraviroc and/or rapamycin in a mouse model of fragility.
%D 2020
%U http://hdl.handle.net/10668/15471
%X As age increases, the risk of developing fragility also increases. Improving the knowledge of frailty could contribute to maintaining the functional ability of elderly people. Interleukin (IL)-10 homozygous knockout mice (IL-10tm/tm [IL10KO]) constitute an excellent tool for the study of frailty. Because patients with frailty demonstrate an overexpression of CCR5, rapamycin (RAPA) and/or maraviroc (MVC), two molecules able to decrease CCR5 expression, were evaluated. Muscle myostatin was reduced in all the therapeutic groups but the MVC group (p  MVC and RAPA show a protective role in some factors involved in frailty. More studies are needed to prove their clinical applications. Eighty male homozygous IL10KOs were randomly assigned to one of 4 groups (n= 20): i) IL10KO group (IL10KO); ii) IL10KO receiving MVC in drinking water (MVC group), iii) IL10KO receiving RAPA in drinking water (RAPA group), and finally, iv) MVC-RAPA group that received MVC and RAPA in drinking water. Blood and muscle samples were analysed. Survival analysis, frailty index calculation, and functional assessment were also performed.
%K CCR5 antagonist
%K frailty
%K myostatin
%K rapamycin
%~